Sanofi: UBS on hold, maintains target price

(CercleFinance.com) - UBS maintains its neutral rating on the Sanofi stock, with an unchanged target of E100, giving it upside potential of 16% relative to its current price.


Following the group's CMD, the analyst highlights Dupixent's increased guidance and highlighted replacement power.

The healthcare group says that recently launched or soon-to-be-launched pharmaceutical assets should generate over E10bn in annual sales by 2030, to which will be added solid growth for Dupixent and vaccines.

"Sanofi raises it expectations for Dupixent and for assets that could replace Dupixent sales in the future" UBS says.


Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.